- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04995523
Studie om de veiligheid en werkzaamheid van AZD2936 te beoordelen bij deelnemers met gevorderde of gemetastaseerde niet-kleincellige longkanker (ARTEMIDE-01)
Fase I/II, open-label onderzoek naar dosisescalatie en dosisuitbreiding om de veiligheid, farmacokinetiek, farmacodynamiek en werkzaamheid van AZD2936 anti-TIGIT/anti-PD-1-antilichaam te evalueren bij deelnemers met gevorderde of gemetastaseerde niet-kleincellige longkanker
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a first-time-in-human (FTIH), open-label, multicenter, multi-part, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics, and efficacy of rilvegostomig (AZD2936) in adult participants with stage III unresectable or stage IV NSCLC. The study includes 4 parts: Part A (dose escalation) and Parts B-E (dose expansion).
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studie Locaties
-
-
-
Melbourne, Australië, 3000
- Research Site
-
-
-
-
-
Anderlecht, België, 1070
- Research Site
-
Leuven, België, 3000
- Research Site
-
-
-
-
-
Florianópolis, Brazilië, 88034-000
- Research Site
-
Natal, Brazilië, 59075-740
- Research Site
-
Porto Alegre, Brazilië, 90035903
- Research Site
-
Rio de Janeiro, Brazilië, 20231-050
- Research Site
-
São Paulo, Brazilië, 01246-000
- Research Site
-
-
-
-
-
Chengdu, China, 610041
- Research Site
-
Chongqing, China, 400030
- Research Site
-
-
-
-
-
Copenhagen, Denemarken, 2100
- Research Site
-
-
-
-
-
Dijon, Frankrijk, 21079
- Research Site
-
Toulouse, Frankrijk, 31059
- Research Site
-
-
-
-
-
Tbilisi, Georgië, 0112
- Research Site
-
-
-
-
-
Kashiwa, Japan, 227-8577
- Research Site
-
Niigata, Japan, 951-8566
- Research Site
-
Sendai, Japan, 981-0914
- Research Site
-
Tokyo, Japan, 104-0045
- Research Site
-
-
-
-
-
Kuala Lumpur, Maleisië, 59100
- Research Site
-
Kuching, Maleisië, 93586
- Research Site
-
-
-
-
-
Chisinau, Moldavië, MD-2025
- Research Site
-
-
-
-
-
Groningen, Nederland, 9713 GZ
- Research Site
-
Leiden, Nederland, 2333 ZA
- Research Site
-
Utrecht, Nederland, 3584 CX
- Research Site
-
-
-
-
-
Barcelona, Spanje, 08035
- Research Site
-
Madrid, Spanje, 28041
- Research Site
-
Madrid, Spanje, 28027
- Research Site
-
-
-
-
-
Taichung, Taiwan, 40705
- Research Site
-
Taichung, Taiwan, 40201
- Research Site
-
Tainan, Taiwan, 70403
- Research Site
-
Taipei, Taiwan, 110
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10700
- Research Site
-
Chanthaburi, Thailand, 22000
- Research Site
-
Muang, Thailand, 50200
- Research Site
-
-
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Research Site
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Research Site
-
-
-
-
-
Seoul, Zuid -Korea, 03722
- Research Site
-
Seoul, Zuid -Korea, 05505
- Research Site
-
Seoul, Zuid -Korea, 03082
- Research Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Written informed consent
- Aged 18 or above
- Part A and Part B: Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part C and Part D: Stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part E: Stage IV squamous NSCLC not amenable to curative surgery or radiation.
- Documented PD-L1 expression by PD-L1 IHC per local report.
- Part A and Part B: Confirmed progression during treatment with a CPI-including regimen.
- Part C and Part D: No prior I/O treatment for metastatic NSCLC.
- Part E: No prior treatment for metastatic NSCLC.
- ECOG performance status of 0 or 1 at enrolment.
- Life expectancy of ≥ 12 weeks at enrolment.
- Have at least 1 measurable lesion per RECIST v1.1.
- Adequate bone marrow, liver and kidney function
Exclusion Criteria:
- Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion
- Documented test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation)
- Previous treatment with an anti-TIGIT therapy
- Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
- Part A and Part B: Primary or secondary resistance after treatment with 2 or more regiments including a CPI.
- Part C and Part D: Any prior systemic treatment with an immune oncology agent (prior administration of immune-oncology agent for curative intent to treat other invasive malignancy is permitted).
Treatment with one previous systemic chemotherapy will be allowed.
- Part E: Any prior systemic treatment for metastatic NSCLC, including but not limited to chemotherapy, anti-PD-1, anti-PD-L1, anti-CTLA-4.
- Symptomatic central nervous system (CNS) metastasis.
- Thromboembolic event within 3 months prior to enrolment.
- Other invasive malignancy within 2 years prior to screening.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced Non-small Cell Lung Cancer (NSCLC)
Rilvegostomig Intravenous (IV) monotherapy |
Anti-TIGIT/Anti-PD-1 Bispecific Antibody
Andere namen:
|
|
Experimenteel: Dose Expansion Part B: CPI experienced NSCLC
Rilvegostomig IV monotherapy |
Anti-TIGIT/Anti-PD-1 Bispecific Antibody
Andere namen:
|
|
Experimenteel: Dose Expansion Part C: CPI Naive NSCLC
Rilvegostomig IV monotherapy |
Anti-TIGIT/Anti-PD-1 Bispecific Antibody
Andere namen:
|
|
Experimenteel: Dose Expansion Part D: CPI Naive NSCLC
Rilvegostomig IV monotherapy |
Anti-TIGIT/Anti-PD-1 Bispecific Antibody
Andere namen:
|
|
Experimenteel: Dose Expansion Part E: treatment Naive Squamous NSCLC
Rilvegostomig IV monotherapy |
Anti-TIGIT/Anti-PD-1 Bispecific Antibody
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters
Tijdsspanne: Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig
|
A DLT is a toxicity defined by the study protocol that occurs from the first dose of study intervention up to the end of the DLT evaluation period that is assessed as clearly unrelated to the primary disease or intercurrent illness. |
Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig
|
|
Rate of rilvegostomig discontinuation due to toxicity
Tijdsspanne: Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months)
|
Percentage of participants with AEs leading to discontinuation of rilvegostomig |
Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months)
|
|
Objective Response Rate (ORR)
Tijdsspanne: Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)
|
Percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR) according to RECIST v1.1 |
Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
ORR
Tijdsspanne: Part A: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
|
Percentage of participants with a confirmed CR or PR according to RECIST v1.1 |
Part A: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
|
|
Disease control rate (DCR)
Tijdsspanne: Part A, B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).
|
Percentage of participants who have a best objective response of confirmed CR or PR or who have SD lasting for at least a certain time of period after start of treatment |
Part A, B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).
|
|
Duration of response (DoR)
Tijdsspanne: Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
|
The time from first response according to RECIST v1.1 until progression or death in the absence of disease progression |
Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
|
|
Durable response rate (DRR)
Tijdsspanne: Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
|
The percentage of participants according to RECIST v1.1 with a confirmed CR or PR lasting 6 months or more |
Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
|
|
Progression-free survival (PFS)
Tijdsspanne: Part B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).
|
The time from first dose of study intervention until the date of objective disease progression or death in the absence of disease progression |
Part B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).
|
|
Measure the receptor occupancy (RO) of TIGIT and PD-1 on peripheral blood
Tijdsspanne: Part A, B: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B.
|
Evaluation of the target engagement of rilvegostomig in peripheral blood |
Part A, B: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B.
|
|
PK of rilvegostomig: Maximum plasma concentration of the study drug (Cmax)
Tijdsspanne: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
Maximum observed plasma concentration of rilvegostomig |
From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
|
PK of rilvegostomig: Area under the concentration-time curve (AUC)
Tijdsspanne: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
Area under the plasma concentration-time curve |
From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
|
PK of rilvegostomig: Clearance
Tijdsspanne: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
A pharmacokinetic measurement of the volume of plasma from which the study intervention is completely removed per unit time. |
From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
|
PK of rilvegostomig: Terminal elimination half-life (t 1/2)
Tijdsspanne: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
Terminal elimination half life |
From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
|
Incidence of anti-drug antibodies (ADA) against rilvegostomig in serum
Tijdsspanne: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
Immunogenicity of rilvegostomig |
From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata per site
- Neoplasmata
- Ziekten van de luchtwegen
- Longziekten
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Neoplastische processen
- Longneoplasmata
- Carcinoom, bronchogeen
- Bronchiale neoplasmata
- Pathologische aandoeningen, tekenen en symptomen
- Neoplasma metastase
- Carcinoom, niet-kleincellige long
- Parkinson Disease 4, autosomaal dominant Lewy Body
Andere studie-ID-nummers
- D7020C00001
- 2021-000857-23 (EudraCT-nummer)
- 2023-508262-15-00 (Register-ID: EU CT Number)
- 2023 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-tijdsbestek voor delen
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-toegangscriteria voor delen
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level datain an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .